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Administration of adipose-derived stromal/stem cells (ASCs) represents a promising therapeutic
approach for autoimmune diseases since they have been shown to have immunomodulatory prop-
erties. The uncultured, nonexpanded counterpart of ASCs, the stromal vascular fraction (SVF), is
composedof a heterogeneousmixture of cells. Although administration of ex vivo culture-expanded
ASCs has been used to study immunomodulatory mechanisms in multiple models of autoimmune
diseases, less is known about SVF-based therapy. The ability of murine SVF cells to treat myelin
oligodendrocyte glycoprotein35–55-induced experimental autoimmune encephalitis (EAE) was com-
paredwith that of culture-expanded ASCs in C57Bl/6Jmice. A total of 1 106 SVF cells or ASCs were
administered intraperitoneally concomitantly with the induction of disease. The data indicate that
intraperitoneal administration of ASCs significantly ameliorated the severity of disease course. They
also demonstrate, for the first time, that the SVF effectively inhibited disease severity and was
statistically more effective than ASCs. Both cell therapies also demonstrated a reduction in tissue
damage, a decrease in inflammatory infiltrates, and a reduction in sera levels of interferon- and
interleukin-12. Based on these data, SVF cells effectively inhibited EAE disease progression more
than culture-expanded ASCs. STEM CELLS TRANSLATIONAL MEDICINE 2013;2:789–796
INTRODUCTION
Multiple sclerosis (MS) is an autoimmunedisease
characterized by inflammatory demyelinating le-
sions, extensive mononuclear cell infiltration
into the central nervous system (CNS), and loss of
motor function. Despite improved understand-
ing of the mechanisms by which MS is mani-
fested, current treatment options for this dis-
ease (such as interferon--1a, interferon-1,
glatiramer acetate, fingolimod, mitoxantrone,
and natalizumab) have limited efficacy in provid-
ing symptomatic relief and complete remission,
especially in patients affected with the chronic
form of MS [1, 2]. The application of adult stem
cells as a potential treatment in MS patients has
been of recent interest, especially for patients
who do not respond to the pharmacologic immu-
nosuppression regimenswith steroids or cortico-
tropin.
Adipose tissue makes up one of the largest
organs in the body and serves as an important
endocrine organ regulating many facets of ho-
meostasis [3–5]. Made up of mature adipocytes
and other nonadipocyte cells, adipose tissue can
bemanually disrupted and/or treated with colla-
genase to isolate the stromal vascular fraction
(SVF). Although not a fully defined cell popula-
tion, the SVF includes vascular smooth muscle
cells, fibroblasts, mast cells, macrophages, lym-
phocytes, endothelial cells, preadipocytes, and
adipose-derived stromal/stem cells (ASCs) [5–
10]. There is an increasing interest in the biology
and therapeutic potential of SVF because of the
direct and rapid isolation procedure in a xenobi-
otic-free environment [9, 11–13].
The SVF can also be cultured in plasticware to
select and expandASCs. ASCs are a fibroblast-like
adherent cell population; these cells maintain
their characteristics for several passages and can
be induced to differentiate into several cell types
in vitro, including adipocytes, chondrocytes, os-
teoblasts, cardiomyocytes, smooth muscle cells,
hepatic cells, endothelial cells, and neuronal-like
cells [14–22]. Comparable to the better studied
bone marrow stromal cells (BMSCs), ASCs have
similar self-renewal abilities, common surface
epitopes, growth kinetics, and cytokine expres-
sion profiles [4, 14, 23–25].Whereas the harvest-
ing of BMSCs has been associated with morbid-
ity, pain, and low yield, ASCs can be obtained at a
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high yield (the yield of stem cells per tissue volume is 100–500-
fold higher in adipose tissue than bone marrow) with minimal
discomfort under local anesthesia [11, 26–28]. In addition, re-
cent data indicate that ASCs are potently immunomodulatory,
making them an appealing candidate for regenerative medicine
and tissue engineering [4, 29].
Both ASCs and SVF cells have been used clinically to treat
acute and chronic diseases afflicting a range of tissues and or-
gans, including soft tissue defects, breast reconstruction, and
autoimmune disease [3, 11]. Anti-inflammatory and regenera-
tive effects of nonexpanded SVF cells have yielded promising
results in canine osteoarthritis and equine tendon ligament inju-
ries [30]. With the encouraging outcomes in clinical work, it is
essential to examine the effects andmechanisms of SVF and ASC
treatment in amurinemodel. Themyelin oligodendrocyte glyco-
protein (MOG)35–55-induced experimental autoimmune enceph-
alomyelitis (EAE) in C57Bl/6J mice correlates to chronic, progres-
sive MS and is an appropriate model to investigate the effects of
treatment with ASCs or SVF [31, 32]. Although it has been re-
ported that mesenchymal lineage stem cells from the bonemar-
row have a therapeutic impact in the EAE model, to date, only a
single study has investigated murine ASCs, and SVF has not been
assessed [33–38]. The goal of this study was to directly compare
SVF cells with ASCs as interventions for disease progression in
the EAE model.
MATERIALS AND METHODS
Cell Isolation and Culture
Isolation of Stromal Vascular Fraction
Subcutaneous white adipose tissue was collected frommale en-
hanced green fluorescence protein (eGFP) transgenic mice
(C57Bl/6-Tg(UBC-GFP)30Scha/J strain; Jackson Laboratory, Bar
Harbor, ME, http://www.jax.org), ranging in age from 2 to 6
months. Adipose tissue was washed in Hanks’ balanced saline
solution (HBSS; Life Technologies, Grand Island, NY, http://www.
lifetech.com), minced with a scalpel, and treated with 0.1% (wt/
vol) collagenase type I (Sigma-Aldrich, St. Louis, MO, http://
www.sigmaaldrich.com) in HBSS for 2 hours, while shaking at
160 rpm at 37°C. The collagenase was neutralized with pre-
warmed complete culture medium (CCM) that consisted of Dul-
becco’s Modified Eagle Medium:Nutrient Mixture F-12 (Life
Technologies), 20% fetal bovine serum (Atlanta Biologicals, Law-
renceville, GA, http://www.atlantabio.com), 100 units/ml peni-
cillin (Life Technologies), 100g/ml streptomycin (Life Technol-
ogies), and 2 mM L-glutamine (Life Technologies). Digested
tissue was filtered through a 70-m-pore cell strainer (Bec-
ton, Dickinson and Company, Franklin Lakes, NJ, http://www.
bd.com) to remove debris. Cells were spun at 400g for 10
minutes, and cell numbers and viability were counted with
trypan blue.
Isolation and Expansion of ASCs
The stromal vascular fractionwas plated in CCM in a 75-cm2 flask
(Corning Enterprises, Corning, NY, http://www.corning.com)
and incubated at 37°C with 5% humidified CO2. After 24 hours,
nonadherent cells were removed by washing with phosphate-
buffered saline (PBS) and fresh CCM. When cells (passage 0)
reached 70%–80% confluence, cells were subcultured by lifting
with 0.25% trypsin/1 mM EDTA (Gibco, Grand Island, NY, http://
www.invitrogen.com) and plated (passage 1) at 100 cells per cm2
in CCM on a 150-cm2 tissue culture dish (Nunc, Rochester, NY,
http://www.nuncbrand.com). Medium was replaced every 3–4
days, and cultureswere splitwhen cells reached 70%confluence.
For all experiments, subconfluent cells (70% confluent) be-
tween passage 2 and passage 6 were used.
Colony-Forming Unit Assay
ASCs were plated at 100 cells on a 10-cm2 plate in CCM and
incubated for 14 days at 37°C with 5% humidified CO2. Plates
were then rinsed three times with PBS, and 3 ml of a 3% crystal
violet solution (Sigma-Aldrich)was added for 30minutes at room
temperature. The plates were washed three times with PBS and
once with tap water. Only the colonies that were 2mm2 ormore




ASCs were cultured in six-well plates in CCMuntil 90% confluent.
Mediumwas then replacedwith freshmedium containing adipo-
genic supplements, consisting of 1 M dexamethasone (Sigma-
Aldrich), 5 g/ml insulin, 0.5 mM isobuytlmethylxanthine (Sig-
ma-Aldrich), and 50 M indomethacin (Sigma-Aldrich) and
changed every third day. After 3 weeks, cells were fixed in 10%
formalin for 1 hour at 4°C and stained for 15 minutes at room
temperature with Oil Red O (Sigma-Aldrich), and images were
acquired on a Nikon Eclipse TE200 (Nikon, Melville, NY, http://
www.nikon.com) with a Nikon DXM1200F digital camera using
Nikon ACT-1 software, version 2.7. Images were acquired at a
magnification of10.
Osteogenic Differentiation
ASCs were cultured in six-well plates in CCMuntil 90% confluent,
and then the medium was replaced with medium containing os-
teogenic supplements, which consisted of 50 M ascorbate
2-phosphate (Sigma-Aldrich), 20 mM -glycerol phosphate (Sig-
ma-Aldrich), 50 ng/ml L-thyroxine sodium pentahydrate, and 1
nM dexamethasone. After 3 weeks, cells were fixed in 10% for-
malin for 1 hour at 4°C and stained for 10 minutes with 40 mM
alizarin red (pH 4.1) to visualize calcium deposition in the extra-
cellular matrix. Images were acquired on a Nikon Eclipse TE200
with a Nikon DXM1200F digital camera using Nikon ACT-1 soft-
ware, version 2.7. Images were acquired at a magnification of
10.
Flow Cytometry
ASCs were harvested with 0.25% trypsin/1 mM EDTA (Gibco) for
4 minutes at 37°C. A total of 3 105 cells were concentrated by
centrifugation at 500g for 5 minutes, suspended in 100l of PBS
containing 1% (wt/vol) bovine serum albumin, and incubated at
room temperature for 30 minutes with a panel of monoclonal
antibodies specific for CD106, CD29, Sca-1, CD31, CD11b, and
CD45. All monoclonal antibodies were purchased from BD
Pharmingen/BD Biosciences (San Jose, CA, http://www.
bdbiosciences.com). The samples were then analyzed by
FACScan (FACSCalibur; BD Biosciences) with CellQuest software.
The SVF was characterized using the same method with the
monoclonal antibodies to the following: CD14, CD16, CD18,
CD25, CD36, CD44, CD146, CD117, Mac-1, F4/80, and Foxp3 (all
purchased from eBioscience Inc., San Diego, CA, http://www.
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ebioscience.com) and CD3, CD4, CD8 CD11b, CD19, CD31, CD34,
and CD45 (purchased from BD Pharmingen). A minimum of
10,000 events were analyzed and compared with isotype con-
trols.
EAE Induction and Treatment Protocols
All animal experiments were approved by Tulane University
School of Medicine’s Institutional Animal Care and Use Commit-
tee and were conducted in accordance with the U.S. Public
Health Service Policy on Human Care and Use of Laboratory An-
imals. Female C57Bl/6 mice, 6–8 weeks old, were purchased
from Charles River Laboratories (Wilmington, MA, http://www.
criver.com). Chronic EAE was induced in these animals by
subcutaneous immunization with 200 l of 200 ng MOG35–55
(AnaSpec, San Diego, CA, https://www.anaspec.com) mixed 1:1
in Complete Freund’s adjuvant with 8 mg/mlMycobacterium tu-
berculosis H37RA (BD DIFCO, Franklin Lakes, NJ, http://www.bd.
com), and 100l was injected subcutaneously at each side of the
base of the tail. Mice also received 100 l of 200 ng of pertussis
toxin (List Biological Laboratories, Campbell, CA, http://www.
listlabs.com) by intraperitoneal (i.p.) injection concomitantly and
again 2 days later. To evaluate the clinical and pathological effi-
cacies of ASCs and SVF in chronic EAE, cells were administered
concomitantly with disease induction. Concurrently with dis-
ease induction, 100 l of 1 106 cells suspended in HBSS was
injected with a 27-gauge needle into the left side of the peri-
toneal cavity during EAE induction (day 0). Sham-treated,
EAE-induced mice received equal volumes of HBSS without
cells.
Clinical Scoring and Statistical Analysis
Naïvemice, EAE sham-treatedmice, EAEmice treatedwith ASCs,
and EAE mice treated with SVF each had 12 mice per group and
were monitored daily for clinical signs of disease by three inde-
pendent, blinded investigators. Clinical scores were based on a
scale of 0–5, with a score of 0 indicating no disease; 1, limp tail
(loss of tail tone); 2, hind limb weakness; 3, partial hind limb
paralysis; 4, complete hind limb paralysis; and 5, moribund or
dead.No animalswere excluded fromanalysis. Clinical scores are
presented as mean  SEM for each group, with dead animals
given a score of 5 on the day of death and for the remainder of
the experiment. Statistical analysis was determined by two-way
ANOVA on days 10–14 and again on days 26–30 using GraphPad
Prism version 4.0b (GraphPad Software, Inc., San Diego, CA,
http://www.graphpad.com). Significance was assumed if the p
value was.01. The disease onset, disease incidence, andmean
maximum scores were recorded for each mouse and expressed
as mean  SD. The cumulative disease score was calculated by
summing the daily clinical score for each mouse during the
course of observation.
Tissue Processing and Histological Analysis
After 30 days after disease induction, 5 of the 12 animals per
group were euthanized by exposure to CO2 and perfused with
sterile PBS. The lumbar and sacral regions of the spinal cords
were removed, postfixed in 10% formalin (Thermo Fisher Scien-
tific, Waltham, MA, http://www.thermofisher.com), and then
embedded in paraffin. Sections were cut at 6-m thickness on a
microtome and stained for hematoxylin and eosin (H&E; Thermo
Fisher Scientific) to reveal perivascular inflammatory infiltrates
and Luxol Fast Blue/Cresyl Violet (LFB; IHC World, Ellicott City,
MD, http://www.ihcworld.com) and Toluidine Blue (Thermo
Fisher Scientific) for myelin detection. Histological analysis was
performed on a Nikon Eclipse E800 microscope, acquired with
Slidebook version 5.0 software (Olympus, Center Valley, PA,
http://www.olympus-global.com), and analyzed using Fiji/
ImageJ software. Quantification for each stainwas performedon
nine random sections per animal and five animals per group. All
images were analyzed by investigators blinded to the status of
the animal. The demyleination score was measured by the ratio
of area of intact myelein against the same values for the naïve
group, which was set to 1. An index of cellular debris was deter-
mined by the percentage of positive pixels divided by the per-
centage of positive pixels of the naïve group, which was set to 1.
The percentage of inflammatory infiltrates wasmeasured by the
number of total cells (i.e., cells 5m2) per field at amagnification
of400.
Cytokine Detection
At 30 days after disease induction, blood was collected from all
mice during intracardial perfusions. Cytokines were analyzed by
ELISA Immunoassay (Life Technologies), according to the manu-
facturer’s instructions. Briefly, serum was added in 96-well pre-
coated plates and incubated at room temperature. After wash-
ing, a specific polyclonal antibody followed by substrate solution
was added, and the color development wasmeasured at 450 nm
on a fluorescent microplate reader (FLUOstar optima; BMG
Labtech Inc., Durham, NC, http://www.bmglabtech.com). The
concentration of cytokines was calculated using the standard
curve. Statistical analysis using a two-tailed Student’s t test was
performed to evaluated differences between groups. Signifi-
cance was assumed if the p value was.05.
RESULTS
Characterization of the Fat Stromal Vascular Fraction
Subcutaneous adipose tissue obtained from 2–6-month old
male eGFP transgenic mice was processed by collagenase diges-
tion and differential centrifugation. Approximately 0.55 0.21 g
of adipose tissue was harvested per mouse, averaging 1.82 
106  9.9  104 mononuclear SVF cells per gram of adipose
tissue, with a viability between 89% and 94% when measured
with trypan blue (data not shown). After lysing red blood cells,
the cell populations in the SVFwere analyzed for the presence of
lineage-specific markers via flow cytometry. The most abundant
populations detected were committed adipocyte progenitors
(26.26%) and ASCs (21.38%; Table 1). Additionally, 24.31% ex-
pressed leukocytemarkers, 7.98% of cells expressed hematopoi-
etic stem cell-like markers, and 4.20% expressed T-cell markers.
Cells below detectable levels (2%) included the following: en-
dothelial cells, vascular smooth muscle cells, B cells, mast cells,
granulocytes, monocytes, macrophages, natural killer cells, and
T-regulatory cells.
Characterization of Cultured Adipose-Derived Stem
Cells
In passage 1 after the initial plating of the SVF cells, ASCs ap-
peared as a monolayer of large, flat cells and had a mean dou-
bling time of 55.2  4.8 hours. At passage 2, cells acquired a
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spindle shape, appeared fibroblast-like, and had a mean dou-
bling time of 81.6 4.8 hours. From passage 2 on, the morpho-
logical appearance and length of doubling time was maintained
during subsequent passages.
To demonstrate the multipotent differentiation potential
of ASCs, passage 2 cells were induced to differentiate into
adipogenic and osteogenic lineages. When ASCs were cul-
tured in adipogenic medium for 3 weeks, more than 50% of
the cells became lipid-retaining cells that stained positive
with Oil Red O (Fig. 1A, middle). In osteogenic medium, more
than 30% of the cells were induced into an osteogenic lineage
confirmed by alizarin red staining (Fig. 1A, right). The ASCs
successfully generated colony-forming units by generating an
average of 20  4.6 colonies per plate when plated at 100
cells on a 10-cm2 plate (Fig. 1B). ASCs were phenotypically
defined as90% positive for CD29 and Sca-1, 60%–80% pos-
itive for CD106, and negative ( 2% positive) for CD31,
CD11b, and CD45 via flow cytometry (Fig. 1C).
Intraperitoneal Injection of ASCs or SVF Ameliorates
MOG35–55-Induced EAE
To evaluate whether the SVF cells or ASCs could affect disease
progression in an autoimmune disease such as EAE, a preventa-
tive protocol was investigated in which cells were administered
i.p. at the time of disease induction. Both SVF treatment and ASC
treatment halted disease progression when compared with con-
trols treated with vehicle alone, resulting in a statistically signif-
icant reduction of cumulative disease scores (Fig. 2; Table 2). On
average, control mice developed the first clinical signs at 9 days
postinduction (DPI), peaked around day 14 with hind limb paral-
ysis, and then presented a stable disease course, typical of this
model (Fig. 2; Table 2). Mice treated with ASCs had a slight but
statistically insignificant delayed onset of disease comparedwith
controls, with the average first clinical signs appearing at 9.3 DPI.
EAE mice treated with SVF cells had a drastic delay in disease
onset (14 DPI). It is important to note that only 3 of the 12 exper-
imental animals treated with the SVF demonstrated clinical
signs, which first presented at 10 DPI. Although the mean maxi-
mum score of the ASC-treated group was not significantly differ-
ent compared with SVF-treated mice (1.9  0.7 vs. 1.7  0.9,
respectively), the disease incidence was vastly altered. Only one
of the SVF-treated mice reached a clinical score of 3, which pre-
sented only for 3 days, and then reduced to a clinical score of 2
for the remainder of the disease course (Fig. 2B). These data
suggest that the i.p. injection of ASCs or SVF cells results in de-
layed and reduced disease severity. Moreover, it also indicates
the SVF cells have a very potent neuroprotective effect in chronic
EAE.
Pathological Features Are Diminished With SVF or ASC
Treatment
To determine whether the reduced disease severity correlated
with pathological features, spinal cords from naïve, HBSS-
treated, ASC-treated, and SVF-treated EAE mice were stained
with Luxol Fast Blue to analyze regions of demyelination. Quan-
tification was performed on nine sections per animal and five
animals per group. All images were analyzed by investigators
blinded to the status of the animal. Indexes were normalized to
the average value obtained in naïve mice (set to 1).
The extent of demyelinated regions was reduced in both the
SVF-treated (score of 0.77) and ASC-treated mice (score of 0.84)
compared with control EAE-treated mice (score of 0.68) (Fig. 3;
Table 2). Similarly, both treatment groups demonstrated re-
duced myelin breakdown products and debris compared with
controls (an index of 1.8 in ASC-treated mice and 1.0 in SVF-
treated mice, compared with 6.1 in controls), consistent with a
neuroprotective effect of both cell therapies in EAE (Fig. 3; Table
2). The influx of immune infiltrates was measured by H&E stain-
ing of spinal cords. The percentage of infiltrating cells was signif-
icantly decreased in animals treated with either ASCs (7.9%) or
SVF (8.5%) compared with controls (14.6%), indicating that both
cell treatments are also capable of reducing inflammatory cell
infiltrates into the CNS during EAE induction (Fig. 3; Table 2).
SVF and ASCs Both Suppressed Interferon- and
Interleukin-12 in the Sera of EAE Mice
Tumor necrosis factor- (TNF), interleukin-12 (IL-12), and inter-
feron- (IFN-) are cytokines that have been shown to be re-
sponsible for Th1 cell stimulation and that play a central role in
the pathology ofMS and EAE [39, 40]. To determinewhether the
protective effect of ASC or SVF treatment was related to these
factors, levels in the sera were assayed by enzyme-linked immu-
nosorbent assay. Although the IFN- sera levels of ASC-treated
(51.33 pg/ml) and SVF-treated (54.46 pg/ml) mice were both
lower than in the control (77.71 pg/ml), the two experimental
groupswere not statistically significant between each other. Nei-
ther ASC nor SVF treatment affected TNF levels. The IL-12 sera
levels were significantly decreased in ASC-treated mice (79.26
pg/ml) and further decreased in SVF-treated mice (35.57 pg/ml)
compared with control mice (235.18 pg/ml) (Fig. 4). Collectively,
these data suggest that ASC and SVF treatment can decrease
serum levels of Th1-type inflammatory cytokines, such as IL-12
and IFN-.
DISCUSSION
Multipotent marrow stromal cells (MSCs) are a promising ther-
apy for the treatment of autoimmune diseases of the CNS be-
cause of their immunomodulatory and neuroprotective effects.
BMSCs, the most studied type of MSCs, have demonstrated the
ability to ameliorate both chronic and relapsing-remitting EAE
[36, 41, 42]. In both experimental conditions, BMSCs have shown
Table 1. Characterization of stromal vascular fraction from
C57BL/6 mice









T cell CD45CD34CD3 4.2
T-regs CD4Foxp3CD25 ND (1.99)
EC-like CD34CD31CD146 ND (1.99)
Monocyte CD14CD45 ND (1.99)
Vascular smooth muscle cell CD34dimCD31CD146 ND (1.99)
B cell CD45CD34CD19 ND (1.99)
Mast cell CD45CD34CD117 ND (1.99)
Granulocyte CD45CD11b ND (1.99)
Macrophage F4/80Mac1CD11b ND (1.99)
NK cells CD8CD16CD3 ND (1.99)
Abbreviations: ASC, adipose-derived stromal/stem cell; EC, endothelial
cell; HSC, hematopoietic stem cell; ND, not detected; NK, natural killer;
T-regs, T-regulatory cells.
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to be effective by immune suppression exerted on autoreactive
B and T cells and inducing a Th2-polarized immune response [33,
35, 36, 42, 43]. However, the source and availability of MSCs is
becoming a crucial issue for their clinical application. Although
BMSCs have demonstrated promising results, the invasive na-
ture of bone marrow biopsies may limit their practicality for
wider clinical applications. Since adipose tissue contains a large
number of ASCs, is easy to obtain in large quantities, and is easily
accessible, it has become an appealing cell source for regenera-
tive medicine and tissue engineering. ASCs have been shown to
holdmany of the sameproperties of BMSCs, such as the ability to
differentiate, inhibit T-cell activation and proliferation, and pro-
duce anti-inflammatory molecules, and have been shown to aid
in tissue repair through the secretion of cytokines [16]. The un-
cultured counterpart of ASCs, the SVF, is a particularly promising
candidate for regenerative medicine because the cells can be
isolatedwithin hours of obtaining the lipoaspirate and no culture
expansion of the cells is required, which would reduce any po-
tential risks associatedwith growing cells in vitro and remove the
need for complex laboratories. In addition to the clinical risks of
ex vivo expansion, the variables used in cell culture, such as per-
centage and source of serum used, type of basal medium, me-
dium supplements, culture surface substrate, cell seeding
density, passage number, and confluence of culture, are un-
doubtedly giving rise to contrasting and confusing results in re-
search. They also contain a heterogeneous population of cells,
each type of which may independently contribute or work syn-
ergistically together, providing a beneficial effect.
Although the use of ASCs and SVF cells has been investigated
in alleviating symptoms in autoimmune diseases such as graft-
versus-host-disease, rheumatoid arthritis, Crohn’s disease, and
stroke, few studies have investigated ASCs or SVF cells in the
treatment of MS or its mouse model EAE [18, 30]. One group
showed that murine ASCs had a significant beneficial effect on
chronic EAE by acting simultaneously in the lymphoid organs as
well as the inflamed CNS and causing a dramatic change in anti-
gen-specific T-cells [37]. Another group, Riordan et al., demon-
strated improved function in MS patients treated with SVF [30].
Figure 1. Characterization of mouse adipose-derived stem cells from C57Bl/6 stromal vascular fraction. Adipose-derived stromal/stem cells
(ASCs) were grown in complete culture medium (CCM) until they were 70% confluent and then switched to differentiation medium. After 21
days, cells were fixed and stained with alizarin red for osteogenesis and Oil Red O for adipogenesis. Representative images for each group are
shown (A). Magnification is10 for all panels. (B): CFUs were seeded at a density of 100 cells per 10-cm2 dish and incubated in CCM for
14 days. Cells were fixed and stained with crystal violet. A representative image is shown. (C): ASCs were stained with antibodies against
the indicated antigens and analyzed by flow cytometry. Each experiment was performed in triplicate. Abbreviation: CFU, colony-
forming units.
Figure 2. Clinical evaluationofASCor SVF treatment inmyelin oligodendrocyte glycoprotein35–55-inducedexperimental autoimmuneencephalitis.
(A): Improved clinical scoreswere seen in both ASC-treated (F) and SVF-treated ()mice comparedwith controls (Œ). Values aremeans from three
independent reviewers. Bars indicateSEM. , p .01, comparing controls and ASC-treated mice; F, p .01 between controls and SVF-treated
mice;Œ, p .05 between SVF-treated and ASC-treated mice. (B): Left: The clinical scores at day 14 DPI show the distribution during peak disease,
demonstrating that themajority of SVF-treatedmicedisplayedno symptomsandASC-treatedmice showeddecreased symptoms. Right: The clinical
scores at the end of the course show that the treated groups stablymaintained their reduced state of disease. Abbreviations: ASC, adipose-derived
stromal/stem cell; DPI, days postinjury; SVF, stromal vascular fraction.
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Figure 3. Treatment with SVF or ASCs reduces cellular infiltration and tissue damage in experimental autoimmune encephalitis (EAE). Spinal
cords from Hanks’ balanced saline solution (HBSS)-treated, ASC-treated, SVF-treated, and naïve mice were obtained after euthanasia at 30
days postinjury and processed for histological staining using Luxol Fast Blue (LFB), Toluidine Blue (TB), andH&E. Quantificationwas performed
on nine random sections per animal and five animals per group. LFB staining identified multiple areas of demyelination in HBSS-treated EAE
mice but only scattered foci in both treated groups. Similarly, sections labeled with TB showed increased myelin debris and greater numbers
of demyelinated axons in the control mice compared with naïve or treated mice. Comparisons of the H&E images show a decrease in the
number of infiltrating immune cells in the spinal cord after administration of both ASCs and SVF. Abbreviations: ASC, adipose-derived
stromal/stem cell; H&E, hematoxylin and eosin; SVF, stromal vascular fraction.
Figure 4. Serum levels of inflammatory cytokines. At 30days after disease induction, bloodwas collected fromallmiceduring intracardial perfusionand
analyzedby ELISA Immunoassay. IL-12 levelswere decreased inASC-treatedmice and further decreased in SVF-treatedmice comparedwith controlmice
(middle).Bothtreatmentgroupshadasimilardecreasein levelsof IFN- (left).NodifferencewasseeninTNF (right).Bars indicateSD.†,p .05between
controls and SVF-treated mice; ‡, p .05 between controls and ASC-treated mice; , p .05 between treatment groups. Abbreviations: ASC, adipose-
derived stromal/stemcell; IFN-, interferon-; IL-12, interleukin-12; SVF, stromal vascular fraction; TNF, tumornecrosis factor-.

















Control 9.0  1.0a (7–10) 12/12 (100) 3.5  0.5b (3–4) 30.4  9.57a 14.62  6.6 0.68  0.3b 6.15  0.69b
ASCs 9.3  1.1 (8–10) 7/12 (58) 1.9  0.7 (0–4) 13.05  9.6 7.9  5.5 0.84  0.2 1.83  0.2
SVF 15  4.5 (10–30) 3/12 (25) 1.7  0.9 (1–3) 9.4  9.0 8.54  6.9 0.77  0.1 1.06  0.2
ap .05 between control group and SVF-treated group.
bp .05 between control group and both experimental groups.
Abbreviations: ASC, adipose-derived stromal/stemcell; DPI, days postinduction; EAE, experimental autoimmuneencephalitis; SVF, stromal vascular fraction.
794 Comparison of SVF with ASCs in EAE
©AlphaMed Press 2013 STEM CELLS TRANSLATIONAL MEDICINE
However, themechanism and effects of SVF therapy are not well
understood, and a comparison of uncultured versus ex vivo-ex-
panded cells in the treatment of EAE has yet to be evaluated.
Furthermore, quantitative and statistically significant data are
lacking in animal models used to determine mechanism and ef-
fects.
This study is among the first to show that ASCs have a signif-
icant beneficial effect in preventing chronic EAEnot onlywhenex
vivo-expanded but also without expansion. Although in both
cases, the amelioration of clinical scores was accompanied by a
strong reduction of spinal cord inflammation, demyelination,
and axonal damage, the SVF cells provided a significant reduction
in incidence of disease compared with their ex vivo-expanded
counterpart.
Characterizing the molecular mechanisms mediating ASC-
and SVF-based therapy is of critical importance to clinical appli-
cations and represents an important contribution to the under-
standing of ASC- and SVF-based therapy. IFN- is a cytokine
associatedwith a number of autoinflammatory and autoimmune
diseases because of its role in Th1 cell stimulation, differentia-
tion, and function via STAT1 and STAT4 pathways [39]. These
autoreactive T cells play a central role in the direct regulation of
T-cell activation and survival during autoimmune inflammation
in the pathology of MS and EAE [39, 40]. In this study, IFN-was
reduced comparably between treatment groups. These results
point to an effector role of both ASCs and SVF cells, which would
occur during the early inflammatory phase of disease, support-
ing the possibility that ASCs and SVF could both affect the
generation of encephalitogenic effector T cells. Although BM-
SCs have been shown to reduce levels of IFN- by direct con-
tact, it is unclear whether ASCs and SVF cells use the same
mechanism [44]. Although the mechanisms mediating such
effects are still only partially understood, it is likely that they
involve both direct cell-to-cell contact and paracrine signaling
via soluble factors.
In addition to IFN-, IL-12 is responsible for Th1 cell stimula-
tion, differentiation, and function and plays a central role in the
pathology of MS [39]. In this study, IL-12 was reduced in both
treatment groups, but levels were further reduced in the SVF
treatment group compared with the ASC treatment group. Al-
though this is the first study to show that both ASC treatment
and SVF treatment have reduced levels of IL-12, BMSCs have
been shown to reduce levels of IL-12 in a chronic EAE model [44,
45]. Interestingly, murine BMSCs were shown to exert oppos-
ing effects on Th1 cells depending on the time of disease onset
and the level of effector T-cell activation, suppressing all T
cells when administered early in T-cell activation and able to
decrease IFN- and increase IL-17 only when T cells became
activated [46].
These results indicate that IL-12 may play an important
mechanistic role during the increased potency of SVF-based
therapy. It is possible the SVF cells, beyond their ex vivo-ex-
panded counterpart, have the ability to further reduce the level
of effector T-cell activation, keeping the disease progression in
a more naïve state by reducing IL-12 and, therefore, Th1 stim-
ulation and differentiation. It remains unclear whether this is
a result of the ASCs being uncultured and retaining more of
their in vivo properties, whether it is a result of administering
a heterogeneous population, or whether it is a product result-
ing from the interaction of ASCs with one of the other cell
types present.
Although BMSCs have been shown to reduce TNF levels by
direct contact in vitro, this study showed that neither ASCs or SVF
cells affected TNF levels in an EAE model [44]. This may be due
to BMSCs using a different mechanism or the cells being admin-
istered at different time points during T-cell activation and
differentiation. This also reiterates the speculation that the
timing of stem cell interaction with T cells may drastically
change immunomodulatory results and, therefore, disease
progression.
CONCLUSION
Further work needs to address whether it is the uncultured ASCs
in the SVF fraction that have such a potent effect or whether the
effect is a synergistic one with one or more of the other cell
populations found in the SVF fraction. Future studies also need
to further elucidate the mechanism, whether the injected ther-
apeutic cells are causing a shift in the immune response in the
lymphatic system before other pathogenic events via IL-17 or
other notable cytokines, whether the injected therapeutic cells
are influencing the endothelium to prevent breakdown of the
blood-brain barrier and subsequent infiltration of immune cells
into the CNS, or whether the injected therapeutic cells are di-
rectly affecting the myelin breakdown. In conclusion, these find-
ings show that when comparedwith ex vivo-expanded ASCs, SVF
cells are easier and safer to access, further delay and reduce EAE
disease course and pathology, and further reduce Th1-type cy-
tokines. These results show that SVF cells have relevant thera-
peutic potential in an animal model of chronic MS and might
represent a valuable tool for stem cell-based therapy in chronic
inflammatory disease of the CNS.
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